<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522950</url>
  </required_header>
  <id_info>
    <org_study_id>CV-2014-20226</org_study_id>
    <nct_id>NCT01522950</nct_id>
  </id_info>
  <brief_title>A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function</brief_title>
  <acronym>EVIDENCE</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study comparing the efficacy of
      nebivolol and atenolol at improving small artery elasticity and reducing cardiovascular
      disease risk in subjects with early vascular disease. Approximately 75 subjects with
      borderline/elevated blood pressures and impaired endothelial function, as measured by
      arterial elasticity scores, will be recruited and assigned to treatment groups using a block
      randomization scheme. Patients will be randomly allocated to nebivolol, atenolol or placebo,
      and then followed for 9 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Rasmussen Disease Score (RDS) test panel is the chosen methodology for this study. The 10
      parameters of the RDS were selected because of their ability to quantify early structural and
      functional abnormalities in the vasculature and left ventricle which appear long before
      cardiovascular disease is present.

      The RDS tests include: large and small artery elasticity (measured by pulse contour
      analysis), resting blood pressure, mild treadmill exercise test, carotid IMT, left ventricle
      mass, ECG, retinal vasculature evaluation, as well as quantification of serum NT-proBNP, and
      microalbuminuria. Quantitative results from these tests are converted into categorical
      classifications based on values stratified by age and gender when appropriate. The
      categorical data is scored as follows: normal = 0 points, borderline = 1 point, abnormal = 2
      points. Point values from all parameters are summed to create the RDS, with values ranging
      from 0-20. Scores of 0-2 are classified as normal, 3-5 as early disease, and 6+ as advanced
      disease. Previous research has shown that the RDS is a powerful predictor of future
      cardiovascular events.

      The small artery elasticity (C2) parameter is of particular interest as it is responsive to
      changes in NO levels and is an effective and reliable predictor of future hypertension and
      other cardiovascular events. Changes in C2 will serve as the primary outcome of this study.
      Similar studies using anti-hypertensive or lipid-lowering interventions have found
      significant improvements in C2 values.

      Brachial artery flow-mediated dilation (FMD) measurements will also be measured as an index
      of endothelial function, although this method appears to be less sensitive to functional
      changes related to NO bioavailability than C2. Utilizing both FMD and C2 will allow
      comparison with previous studies and take advantage of a large sample size to further examine
      the relative sensitivity of each method for reliably measuring endothelial dysfunction.

      The duration of intervention for this study is 9 months which is the minimum time to
      adequately detect improvement in left ventricle (LV) mass values. LV mass measurements are a
      critical component of a comprehensive assessment of cardiovascular health and have improved
      within this temporal window as a result of anti-hypertensive intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Small Artery Elasticity</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Change in small artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Large Artery Elasticity</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Change in large artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Change in systolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Change in diastolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>5 mg daily or 10 mg daily</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atenolol</intervention_name>
    <description>25 mg daily or 50 mg daily</description>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  borderline blood pressure (120-145/80-90 mm Hg);

          -  borderline or abnormal small artery elasticity (C2) as measured by pulse contour
             analysis;

          -  treatment-naive for all blood pressure medications including diuretics for at least 30
             days prior to baseline visit;

          -  able to walk on a treadmill for 3 minutes;

          -  female patients with reproductive potential must use an approved contraceptive method
             if appropriate (for example, intrauterine device [IUD], birth control pills, or
             barrier device during and for 1 month after the last dose of study drug;

          -  voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

        Exclusion Criteria:

          -  history of intolerance to beta-blockers or clear contraindications to their use;
             current pharmaceutical treatment of blood pressure;

          -  known history of cardiovascular disease (myocardial infarction, coronary artery bypass
             graft, unstable angina, uncontrolled arrhythmias, stroke, etc.);

          -  known history of diabetes; known history of hepatic, renal or gastrointestinal
             disorder;

          -  known history of any illness that may cause additional risk (as determined by study
             investigator);

          -  pregnant or lactating women [when used during pregnancy, beta-blockers may cause fetal
             harm];

          -  participation in a concomitant clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay N Cohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <results_first_submitted>June 4, 2019</results_first_submitted>
  <results_first_submitted_qc>January 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 21, 2020</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>prevention</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01522950/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Atenolol</title>
          <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Medication Sensitivity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Atenolol</title>
          <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="14.5"/>
                    <measurement group_id="B2" value="50.8" spread="14"/>
                    <measurement group_id="B3" value="54" spread="9"/>
                    <measurement group_id="B4" value="50.7" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Small Artery Elasticity</title>
        <description>Change in small artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.</description>
        <time_frame>baseline, 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Small Artery Elasticity</title>
          <description>Change in small artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.</description>
          <units>(ml/mmHg × 100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.1"/>
                    <measurement group_id="O2" value="1.0" spread="2.1"/>
                    <measurement group_id="O3" value="0.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Large Artery Elasticity</title>
        <description>Change in large artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.</description>
        <time_frame>baseline, 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Large Artery Elasticity</title>
          <description>Change in large artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.</description>
          <units>(ml/mmHg × 10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="5.4"/>
                    <measurement group_id="O2" value="2.9" spread="3.4"/>
                    <measurement group_id="O3" value="0.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Change in systolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.</description>
        <time_frame>baseline, 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Change in systolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" spread="12.9"/>
                    <measurement group_id="O2" value="-13" spread="10.6"/>
                    <measurement group_id="O3" value="-3.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <description>Change in diastolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.</description>
        <time_frame>baseline, 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <description>Change in diastolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="10.1"/>
                    <measurement group_id="O2" value="-8.5" spread="8.9"/>
                    <measurement group_id="O3" value="-2.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
Nebivolol: 5 mg daily or 10 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Atenolol</title>
          <description>25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
atenolol: 25 mg daily or 50 mg daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Continue for 1 month; dose titration to &quot;high dose&quot; placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
placebo: one tablet daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jay N. Cohn, M.D., Professor of Medicine</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612.625.5646</phone>
      <email>cohnx001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

